Authors

Manmeet Ahluwalia, Miami Cancer InstituteFollow
Ahmad Ozair, Miami Cancer InstituteFollow

Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT

Publication Date

6-5-2024

Content Type

Article

PubMed ID:

38836759

Additional Authors:

Additional authors and institutional affiliations

Citation

Ahluwalia, M. S., Ozair, A., Drappatz, J., Ye, X., Peng, S., Lee, M., Rath, S., Dhruv, H., Hao, Y., Berens, M. E., Walbert, T., Holdhoff, M., Lesser, G. J., Cloughesy, T. F., Sloan, A. E., Takebe, N., Couce, M., Peereboom, D. M., Nabors, B., Wen, P. Y., … Rogers, L. R. (2024). Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT. Clinical cancer research : an official journal of the American Association for Cancer Research, 10.1158/1078-0432.CCR-23-4098. Advance online publication. https://doi.org/10.1158/1078-0432.CCR-23-4098